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exercise in hypoxia under naloxone: a
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Laurent Koglin1 and Bengt Kayser2*Abstract
Background: Opioid receptors are possibly involved in the perception of exertion and the ventilatory response to
exercise. We compared incremental cycling exercise in conditions of normoxia and hypoxia (11% O2) after injection
of the opioid receptor antagonist naloxone (30 mg i.v.) or placebo. Naloxone was expected to increase sensation of
breathing and cycling and to curtail exercise performance more in hypoxia.
Methods: Ten healthy subjects (29 ± 2 years, 183 ± 6 cm, 75 ± 7 kg, mean ± SD) cycled in normoxia and hypoxia
until voluntary exhaustion, receiving naloxone or placebo in a balanced double-blind crossover design.
Results: Hypoxia decreased peak power output by 37%–39% with placebo and naloxone (P < 0.001, no effect of
naloxone). Switching to normoxia at exhaustion in hypoxia allowed continuing up to 97%–100% of power
developed in normoxia with placebo and naloxone (P < 0.001, no effect of naloxone). Perceived exertion increased
in hypoxia, dropped upon switching to normoxia and increased again towards exhaustion, no effect of naloxone.
SpO2 (earlobe oximetry) was lower in hypoxia, dropping to 64%–68% with naloxone and placebo. The ventilatory
response to exercise in normoxia and hypoxia was not changed by naloxone.
Conclusions: It follows that in healthy subjects the ventilatory response and the perception of exertion in hypoxia
as compared to normoxia do not involve the endogenous opioid system, and the latter does not play a role in
limiting maximum exercise capacity in hypoxia.
Keywords: Altitude, Exercise, Human, Opioid, HypoxiaBackground
In both healthy subjects and patients, dyspnoea and leg
fatigue are the main symptoms limiting exercise capacity
[1-4]. Dyspnoea is accompanied by activation of cortico-
limbic structures implicated in interoceptive awareness
and nociceptive sensations, such as pain, and involves
the opioid system [5]. In patients with dyspnoea,
exogenous opioids can alleviate breathing-related dis-
comfort and improve exercise performance [5-8], while
injection of naloxone hydrochloride, a non-specific
opioid antagonist that crosses the blood–brain barrier,
can decrease performance [5]. Opioids can relieve dys-
pnoea by altering central processing of efferent and* Correspondence: bengt.kayser@unige.ch
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distribution, and reproduction in any mediumafferent sensory information [5]. Sgherza et al. [9] found
that in normoxia, in healthy trained subjects, naloxone
compared to placebo decreased incremental exercise
performance and suggested that sensation of exertion is
under influence of endogenous opioids and may be a
limiting factor for maximum aerobic exercise capacity.
Acute hypoxia is a potent stressor, especially when
combined with an exercise challenge, changing the per-
ceived level of exertion [10]. Acute exposure to hypoxia
increases ventilation and cardiac output in order to min-
imise the reduction in arterial oxygen content and sys-
temic mass oxygen transport. Despite these acute
adaptations, incremental exercise testing in such condi-
tions (e.g. an FiO2 equivalent to an altitude of 5,000 m
or higher, hereafter referred to as severe hypoxia) invari-
ably results in compromised aerobic exercise capacity.
The mechanisms behind this limitation of exercisentral Ltd. This is an Open Access article distributed under the terms of the
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A puzzling observation is that despite maximum effort
in severe hypoxia, cardiac output remains submaximal,
suggesting early motor drive withdrawal [11,12]. How-
ever, while the locomotor muscles are not driven as hard
during large muscle volume effort in such conditions,
the contrary is the case for the respiratory muscles.
Ventilation is higher for any given level of oxygen con-
sumption during exercise in hypoxia, as compared to
normoxia, and is accompanied by a concomitant in-
crease in the sensation of breathing effort [10]. Since
blocking the effect of endogenous opioids on the sensa-
tion of exertion can increase symptom intensity and cur-
tail performance in normoxia [9], it is possible that such
an effect would be exacerbated in hypoxia. We therefore
hypothesised that blocking opioid receptors may de-
crease aerobic exercise performance more in hypoxia
than in normoxia. To test this hypothesis, we compared
incremental cycling exercise in conditions of normoxia and
hypoxia (11% O2) after injection of the opioid antagonist
naloxone in comparison to a placebo. Our expecta-
tions were that under naloxone the sensation of
breathing effort and that of cycling would increase




Thirteen healthy trained men volunteered to participate
in the study. Inclusion criteria were an age between 18
and 30 years and >4 h/week of endurance training. Ex-
clusion criteria were presence of any relevant chronic or
acute disease, having done a maximal capacity training
or a race during the last 48 h, symptoms/signs of viral
illness in the week preceding the experiments or expos-
ure to altitude in the 2 months before the study. The
study was approved by the research ethics commission of
the Geneva University Hospitals and SwissMedic and com-
plied with the principles of the Declaration of Helsinki. All
subjects were screened by a physician, were fully informed
of the nature and risks of the experiments, knew of their
right to withdraw at any time and signed an informed
consent form.
Exercise protocol
After inclusion, the subjects first performed two habitu-
ation experiments, identical to the real experiments ex-
cept for the injection, to get used to the equipment and
to experience cycling in acute hypoxia. They were
instructed not to do any heavy training on the days pre-
ceding the experiments and to refrain from caffeine in
the 4 h preceding a test. To control for circadian
rhythm, for a given subject, all experiments were per-
formed at similar times of the day. After the habituationtests, the subjects came to the lab on four different occa-
sions at least 24 h apart to perform incremental cycling
exercise until voluntary exhaustion, twice in normoxia
and twice in acute normobaric hypoxia (FIO2 = 10.65%
O2, in Geneva the equivalent of an altitude of approxi-
mately 5,000 m). The subjects cycled at 80 rpm on a
mechanically braked ergometer (Monark 282E, Varberg,
Sweden). After 3 min of resting baseline measurements,
the subjects would warm up at 40 watt for 3 min. In
order to obtain similar durations of exercise times be-
tween subjects and between conditions of normoxia and
hypoxia, the duration of steps was adapted between con-
ditions and stages. After warm-up, the subjects incre-
mented by 3-min steps of 40 up to 200 watt in normoxia
and then by 20 watt up to voluntary exhaustion, while in
hypoxia, they incremented by 40 up to 120 watt and
then by 20 watt up to voluntary exhaustion. When
reaching exhaustion in hypoxia, the subjects were
switched to room air (‘normoxia switch’) and strongly
encouraged to continue cycling while the load was
increased by 20 watt every 90 s until reaching secondary
voluntary exhaustion.Intervention
In each condition, they did this once after immediate
pre-exercise intravenous injection of naloxone (30 mg
naloxone HCl in 30 ml saline) and once after placebo
(30 ml saline). The conditions normoxia and hypoxia
were in a randomised order. Naloxone and placebo were
administered in a balanced double-blind crossover de-
sign. The research support section of the Geneva Univer-
sity Hospitals pharmacy prepared the vials, the numbering
scheme and the randomization envelopes and released the
randomization key after data analysis was completed. The
subjects started exercising within 5 min after injection and
reached exhaustion within 30 min, approximately one half
of the serum half-life of naloxone reported in humans [14].Normoxia and hypoxia
Normobaric hypoxia was obtained by mixing N2 into
ambient air under control of FIO2 (Altitrainer, SMTec,
Nyon, Switzerland). The gas-mixing system was attached
via a piece of large-bore low-resistance tubing to the in-
spiratory valve of a low-resistance three-way valve (Hans
Rudolph 2700, Shawnee, KS, USA) mounted in series
with a turbine flow measurement set-up (Vmax 29c,
Sensormedics, Loma Linda, CA, USA) attached to a
tightly fitted face mask (Hans Rudolph). The subjects al-
ways breathed through the same set-up, also in nor-
moxia. The gas-mixing device was set to room air for
the normoxia experiments and to a simulated altitude of
5,000 m for the hypoxia experiments.
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Gas exchange and breathing parameters were measured
breath-by-breath with a metabolic cart (Vmax 29c,
Sensormedics). Prior to each experiment, the system was
calibrated with a 3-L syringe and gas mixtures of known
composition. Heart rate was measured by telemetry with
a thoracic belt (Polar, Tampere, Finland). Arterial blood
haemoglobin saturation (SpO2) was measured on an ear-
lobe with a pulse oximeter (Ohmeda, Helsinki, Finland)
connected to the metabolic cart. Arterialized blood from
a hyperaemic earlobe (Trafuril Cream, Ciba-Geigy, Basel,
Switzerland) was used to measure lactate (Accutrend,
Roche, West Sussex, UK).
To quantify locomotor muscle activation, a surface
electromyogram (EMG) was obtained from the right
vastus lateralis muscle. After cleaning with ether and
light abrading of the skin, two electrodes (Kendall H59P,
Mansfield, OH, USA) were applied directly next to each
other on the distal part of the muscle. In addition to
marking the skin with indelible ink, we used transparent
foil to mark the sites of the electrodes together with skin
marks such as moles and scars to reposition the electrodes
on the same sites between sessions. Inter-electrode resist-
ance was measured and considered acceptable if <3 kΩ. A
reference electrode was placed over a bony area near the
knee. The signal was amplified, filtered with a Butterworth
band pass between 10 and 200 Hz (BMA-830, CWE,
Ardmore, OK, USA), digitised at 1,000 Hz with an AD-
board (NI-Daqcard, National Instruments, Austin, TX,
USA) and stored on a computer. The data were analysed
post hoc with custom routines in Matlab (Matlab, Natick,
MA, USA) to obtain, for each single contraction, the inte-
grated rectified EMG (iEMG) and, after a fast-Fourier
transformation, the median (i.e. centroid, CPF) and mean
power (MPF) frequencies, as described before [15]. iEMG
was normalised with the signal obtained at 80 watt.
Perception of exertion
The subjects were asked to rate the rate of perceived ex-
ertion (RPE) on a 0–10-point CR-10 Borg ratio scale [2].
At the end of each exercise level, the subjects rated their
perception of exertion separately for their legs (How
hard is it to cycle?), breathing (How hard is it to
breathe?) and overall (How hard is the overall effort?).
The anchors were 0 for no exertion at all and 10 for the
maximum imaginable. When prompted, the subject
would point to the scale and nod when the experimenter
called the correct corresponding number out loud.
Analysis and statistics
For each subject and each condition, the data were aver-
aged over the last 30 s of each workload with the excep-
tion of the maximum when a mean over 15 s was used.
The data were analysed with SPSS version 18 (IBM,Chicago, IL, USA). Repeated measures ANOVA was used
to test for within-group effects across time. Following sig-
nificant main effects, planned pairwise comparisons were
made using Holm's sequential Bonferroni procedure.
Results are expressed as mean ± SD. Statistical signifi-
cance was set at P < 0.05.
Results
Of the 13 recruited subjects, 1 dropped out after the first
habituation test (no reason given), 2 subjects were
excluded for a vagal reaction to hypoxia at rest, and 10
completed the study (age 29 ± 2 years (mean ± SD),
height 183 ± 6 cm, weight 75 ± 7 kg, maximum aerobic
capacity (V'O2max) 50 ± 8 ml/kg/min). The injection of
naloxone was well tolerated. Table 1 shows the results
observed at exhaustion in the different conditions.
Hypoxia decreased power output by 39% in the pla-
cebo condition (P < 0.001) and by 37% in the naloxone
condition (P < 0.001, no significant difference between
conditions). Switching to normoxia at exhaustion in hyp-
oxia allowed continuing up to 97% of power developed
in normoxic control under placebo (P < 0.001) and to al-
most 100% under naloxone (P < 0.001, no significant dif-
ference between conditions).
V'O2 peak was 3.77 ± 0.80 L/min (placebo) and 3.85 ±
0.76 L/min (naloxone) in normoxia, reached 2.39 ± 0.4
L/min in hypoxia (both placebo and naloxone) and
increased again to 94% (placebo) and 95% (naloxone) of
normoxia values after the normoxia switch at exhaustion
from hypoxia (no significant difference between condi-
tions). Time to exhaustion was similar in normoxia and
hypoxia (22 ± 3 min) and reached a total of 27 ± 4 min
for hypoxia when adding the additional exercise time
after the normoxia switch (no effects of naloxone).
Figure 1 shows the overall levels of perceived exertion
and those pertaining to breathing and leg effort separ-
ately. In normoxia, perceived exertion increased in a
curvilinear way, and there was no effect of naloxone.
The rate of increase was greater in hypoxia, dropped
upon switching to acute normoxia at exhaustion, and
increased again towards exhaustion (no effect of
naloxone).
The top panel of Figure 2 shows the increase in mi-
nute ventilation (V'E) with exercise intensity and its
more pronounced increase in hypoxia. After the nor-
moxia switch, ventilation dropped but not completely to
the normoxic level. There was no effect of naloxone.
The second panel of Figure 2 shows the evolution of
PETCO2. In conditions of normoxia, the typical pattern
of a slight increase followed by a drop beyond the venti-
latory threshold was observed. Conversely, hypoxia im-
mediately induced hyperventilation and reduced PETCO2
values, which were not restored upon the normoxia
switch. There was no effect of naloxone. The third panel
Table 1 Peak values at exhaustion in normoxia, hypoxia and after the normoxia switch at exhaustion in hypoxia
Normoxia Hypoxia Normoxia switch after hypoxia
Placebo Naloxone Placebo Naloxone Placebo Naloxone
Power (watt) 296 ± 48 292 ± 52 182 ± 36* 184 ± 34* 282 ± 51 291 ± 49
Time (min) 22.5 ± 2.6 22.3 ± 2.4 22.0 ± 3.8 22.4 ± 3.7 27.1 ± 4.2 27.6 ± 3.9
HR (/min) 184 ± 5 181 ± 7 169 ± 7* 168 ± 7* 173 ± 5 170 ± 6
Lactate (mM) 11.3 ± 3.7 10.5 ± 2.4 10.4 ± 2.9 10.3 ± 3.7 11.3 ± 3.0 10.9 ± 5.1
RPE global (a.u.) 9.7 ± 0.5 9.6 ± 0.5 9.4 ± 0.7 9.7 ± 0.5 9.3 ± 0.9 9.4 ± 0.5
RPE resp (a.u.) 9.5 ± 0.7 9.4 ± 0.9 9.5 ± 0.6 9.5 ± 0.7 9.0 ± 1.1 8.9 ± 0.4
RPE legs (a.u.) 9.9 ± 0.3 9.7 ± 0.7 9.6 ± 0.5 9.8 ± 0.4 10.0 ± 0.0 10.0 ± 0.0
SaO2 (%) 91.7 ± 4.1 93.3 ± 6.4 67.5 ± 8.9
* 63.6 ± 8.8* 90.55± 95.70±
PETCO2 (kPa) 4.44 ± 0.70 4.56 ± 0.48 3.50 ± 0.18
* 3.49 ± 0.26* 4.48 ± 0.32 4.42 ± 0.40
V'O2 (L/min) 3.77 ± 0.8 3.85 ± 0.76 2.39 ± 0.40
* 2.39 ± 0.40* 3.53 ± 0.71 3.64 ± 0.63
V'CO2(L/min) 4.92 ± 1.1 4.86 ± 0.80 3.19 ± 0.53
* 3.30 ± 0.57* 3.86 ± 0.78 4.05 ± 0.85
V'E (L/min) 150 ± 33 146 ± 21 128 ± 20
* 133 ± 24* 123 ± 21 132 ± 28
V'A (L/min) 159 ± 43 154 ± 27 133 ± 26
* 137 ± 37* 126 ± 27 138 ± 37
Vt (L) 2.98 ± 0.39 3.16 ± 0.41 2.89 ± 0.51 2.97 ± 0.72 2.91 ± 0.45 3.09±
RR (/min) 50 ± 8 47 ± 7 45 ± 7 44 ± 7 42 ± 6 43 ± 5
MEFR (L/sec) 5.1 ± 1.2 5.0 ± 0.8 4.2 ± 0.7 4.3 ± 0.9 4.1 ± 0.8 4.4 ± 1.0
Naloxone had no effect on any of these parameters in either condition. Power, mechanical power output on cycle ergometer; time, time to exhaustion; HR, heart
rate; lactate, arterialized lactate concentration; RPE, rate of perceived exertion (overall, respiratory, legs); SaO2, earlobe oximetry; PETCO2, end-tidal CO2; V'O2,
oxygen consumption; V'CO2, expired CO2; V'E, minute ventilation; V'A, alveolar ventilation; Vt, tidal volume; RR, respiratory frequency; MEFR, peak expiratory flow.
*Significantly different from normoxia.
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which followed a similar pattern as that of ventilation
and tidal volume (not shown), without any effect of
naloxone.
iEMG was higher during hypoxia (Figure 3). No differ-
ences were observed in CPF or MPF (not shown). At ex-
haustion in hypoxia, after the hypoxia switch, iEMG
increased and reached higher values at exhaustion com-
pared to normoxia. There were no effects of naloxone.
Blood lactate levels (Figure 3) increased in a typical
curvilinear manner both in normoxia and hypoxia, with
an early onset of the exponential increase in hypoxia.
There was no effect of naloxone.
SpO2 showed a slight drop at higher intensities in con-
ditions of normoxia, whereas it dropped right from the
start of exercise in hypoxia. Upon the normoxia switch,
it normalised rapidly. There was no effect of naloxone.
SpO2 reached lower values in hypoxia, dropping to 68%
with placebo and 64% with naloxone (no significant dif-
ference), and increased after the normoxia switch. Heart
rate response to exercise showed the typical linear in-
crease with a steeper slope in hypoxia, a drop at the nor-
moxia switch and similar maximum heart rates at
exhaustion (no effects of naloxone; data not shown).
Figure 4 shows the relationship between ventilation
and RPE breathing, and iEMG and RPE legs. Both rela-
tionships were slightly displaced to the left in hypoxia
compared to normoxia, but there was no effect of
naloxone.Discussion
Contrary to our expectations naloxone had no effect on
any of the investigated variables, neither in normoxia
nor in hypoxia. It follows that, at least in trained healthy
young male subjects, during incremental exercise tests,
in normoxia and normobaric hypoxia with an FIO2 of
10.65 (equivalent to approximately 5,000 m), endogen-
ous opioid receptors are not involved in the ventilatory
and heart rate responses to exercise nor in the sensation
of overall levels of perceived exertion or those pertaining
to breathing or cycling effort specifically.
Naloxone dosage
Could it be that there was insufficient blockade of opioid
receptors? This seems unlikely. The ‘normal’ dose for clin-
ical use of naloxone is 1–4 mg, largely sufficient for full
reversal of the effects of exogenously administered opioids
and to trigger withdrawal symptoms [16]. Naloxone
hydrochloride is partly actively transported through the
blood–brain barrier and reaches higher central nervous
system (CNS) concentrations than in the plasma [17].
Positron emission tomography studies showed that with 1
mg naloxone, 50% of opioid receptors in the CNS were
blocked [18]. Santiago and Edelman [19] recommended a
minimal dose of 0.1 mg/kg for peripheral and central
receptor blockade. We used 30 mg, i.e. 0.40 ± 0.04 mg/kg,
a dose that is four times in excess, to compare our results
to those of a previous study [9]. Naloxone has a half-life of
about 1 h [14]. Our subjects started exercising within 5 min






































































Figure 1 The top panel shows the overall RPE vs. power output.
At exhaustion from exercise in hypoxia, the subjects were switched
to room air and strongly encouraged to continue pedalling until
reaching secondary exhaustion. The arrows indicate the
measurements after the switch; for reasons of legibility, the arrows
are not shown on the other graphs. The middle panel shows the RPE
breathing vs. power output. The bottom panel shows the RPE legs
vs. power output. Error bars were omitted for clarity. The coloured
symbols and lines represent the same conditions for all figures.





















































Figure 2 The top panel shows the total ventilation (V'E) vs.
power output. The middle panel shows the end-tidal CO2 tension
(PETCO2) vs. power output. The bottom panel shows the respiratory
frequency vs. power output.
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largely inside the therapeutic time window. Finally, even
though admittedly anecdotal, several subjects indicated
missing their habitual post-exercise ‘high’ and feeling
somewhat ‘bland’ instead, which after the breaking of the
randomization key appeared to correspond to the nalox-
one experiments, suggestive of naloxone blocking the















































Figure 3 The top panel shows normalised integrated vastus
lateralis surface electromyogram (iEMG) vs. power output. The
middle panel presents the arterialized blood lactate concentration
[La] vs. power output. The bottom panel presents the arterial oxygen
saturation (earlobe oximetry) vs. power output.
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related to the ‘feeling good’ after a workout [20,21].
Opioids and dyspnoea
What can explain the difference between our findings and
the repeated finding of a role for opioids in patients with
dyspnoea? For example, naloxone increased dyspnoeasensation in asthmatics when challenged with metacholine,
and similar findings were reported for chronic obstructive
pulmonary disease (COPD) patients during exercise
[22,23]. Jensen et al. [7] compared inhaled nebulized fen-
tanyl citrate (an opioid analogue) to placebo in COPD
patients and found dyspnoea attenuation and improved ex-
ercise performance. Both sensations of intensity and un-
pleasantness were affected. There are similar observations
in patients with terminal cancer-related dyspnoea [24], and
opioids have a role as therapeutic means in dealing with
dyspnoeic patients in general [5,6,25].
One explanation for an absence of effect in our study
may reside in the complexity of what is covered by the
term dyspnoea. The American Thoracic Society defined
dyspnoea as ‘a subjective experience of breathing dis-
comfort that consists of qualitatively distinct sensations
that vary in intensity’ [5,26]. Dyspnoea includes both
sensory (intensity) and affective (unpleasantness) com-
ponents [26]. Distinct mechanisms and afferent path-
ways are associated with different sensory qualities
(notably work/effort, tightness and air hunger/unsatis-
fied inspiration); distinct sensations most often do not
occur in isolation, and dyspnoea sensations also vary in
their unpleasantness and in their emotional and behav-
ioural significance [5]. In patients, the affective compo-
nent is often of great importance [27], whereas it is of
less significance in a healthy athletic subject during a
non-threatening challenge like an exercise test limited in
time. A patient with COPD associates the difficulty to
breathe during an exercise test with fear to suffocate,
whereas a healthy subject will not [28]. Nevertheless, in
healthy subjects, intravenous morphine sulphate reduces
the discomfort (‘air hunger’) induced by hypercapnia to
a similar extent as observed during clinical studies [25].
Breathing during heavy exercise in severe hypoxia is ac-
companied by dyspnoea with affective aspects [29]. In the
present study, the subjects quantified the rate of perceived
exertion in the classic sense originally proposed by Borg
[2], i.e. the central generated sensation of effort [30].
Affective components of unpleasant sensations related
to the exercise like leg pain or air hunger were not expli-
citly quantified. There are two different dimensions of
exercise-related sensations: (1) one reflecting the sensation
of effort, likely centrally generated and unrelated to affer-
ent feedback and (2) one related to afferent feedback from
various tissues involved in the effort [30]. Aliverti et al.
[10] reported that breathing RPE was uniquely related to
total respiratory power output at low and high altitudes
(hypobaric hypoxia, 4,559 m). In the present study, in con-
ditions of normobaric hypoxia, the tendency for a leftward
shift of the curve relating breathing RPE to V'E (see
Figure 1) suggests that breathing RPE may have been
influenced by other parameters but that the endogenous
opioid system was not involved. However, even if an
Figure 4 The top panel shows RPE breathing vs. total ventilation. The bottom panel shows RPE legs vs. iEMG.
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influenced by hypoxia and/or naloxone in our study, this
did not have an effect on performance.
Ventilatory response to exercise
Anatomical and pharmacological evidence suggests that
endogenous opioids play a role in the control of breathing.
Mu (μ), delta (δ) and kappa (κ) opioid receptors are
present in brainstem areas involved in respiration, and en-
dogenous opioids like endorphins, enkephalins, dynor-
phins and endomorphins are found in medullary and
pontine respiratory regions [6,31]. The depressant effects
of exogenous opioids on ventilation are well known, andalso, endogenous opioids are thought to be tonically active
and have a depressant effect on ventilation [31]. Exogen-
ous opioids also have a strong depressant effect on the
hypoxic ventilatory response in animals and humans [32].
By contrast, on a local CNS level, endogenous opioids
may exert an excitatory modulation of hypoxia-induced
hyperventilation by acting on μ-receptors in the rostral
medullary raphe at least in a rat model [33], illustrating
that the overall systemic effects of exogenous opioids are
not necessarily indicative of the role of endogenous
opioids at specific sites in the CNS. Akiyama et al. [34]
injected healthy subjects with naloxone hydrochloride and
found an increase of both ventilatory (V'E) and mouth
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nia with inspiratory flow-resistive loading. Ward and Nitti
[35] injected the opioid agonist sufentanil in trained ath-
letes during exercise and found that the ventilatory
response to exercise was reduced. We expected that the
injection of 30 mg of naloxone would increase the ventila-
tory response to exercise. Our results indicate no effect of
a general blockade of opioid receptors on the ventilatory
response to incremental exercise in normoxia and hyp-
oxia. It follows that it is unlikely that endogenous opioids
play any important role in the ventilatory response to an
incremental exercise challenge in normoxia and its in-
crease in hypoxia, at least in healthy, young trained male
subjects.
Central effects
Humans frequently report positive feelings during and
after endurance efforts (‘runner's high’) that include both
central effects (improved affect, sense of well-being, anx-
iety reduction, post-exercise calm) and peripheral effects
(reduced pain sensation) [21]. Imaging studies provided
evidence of endogenous opioid release in fronto-limbic
brain regions after physical exercise correlated to per-
ceived euphoria [21]. Endocannabinoids are also thought
to play a role in runner's high [36]. Paulev et al. [37]
compared naloxone (0.8 mg i.v.) to placebo during a
Cooper test (running the longest possible distance
within 12 min) in trained subjects. Performance was not
influenced by naloxone, but perception of muscle pain
was enhanced with naloxone. Sgherza et al. [9] com-
pared incremental exercise capacity in 18 subjects under
naloxone and placebo and reported a significant reduc-
tion with naloxone. They concluded that after naloxone
administration, in laboratory conditions, endurance
trained subjects stop exercise at lower levels than those
under placebo, suggesting that peak exercise capacity
was limited by the individual's perception of exertion,
exacerbated by a lack of effect from endogenous opioids,
rather than by physiological fatigue. Even though several
subjects in our study reported feeling ‘bland’ after exer-
cise under naloxone, we did not see the reduction in
exercise capacity reported by Sgherza et al. [9] in nor-
moxia. Their results were based on 18 subjects, and ear-
lier studies with fewer subjects and lower dosage of
naloxone had failed to find significant effects. We there-
fore cannot exclude that our results, obtained in ten
subjects, are limited by type-II error, but given the ab-
sence of any change in the variables monitored, it seems
quite unlikely that in hypoxia an effect of opioid block-
ade plays any important role.
Leg afferents
Apart from their involvement in noxious signalling,
spinal cord level opioid receptors may play a role in theexercise pressor response. Amann et al. [38-40] used
lumbar intrathecal fentanyl to block central projection
of μ-opioid-receptor-sensitive group III/IV muscle affer-
ents from the lower limbs during different exercises:
single-leg mild to moderate intensity knee extensor exer-
cise, 5-km cycling time trial exercise, incremental cycling
exercise and constant load exercise to exhaustion. Affer-
ent blockade had no effect on central and peripheral
haemodynamics or ventilation at rest, but during exer-
cise cardiac output, mean arterial pressure and femoral
blood flow were attenuated in the knee extensor exer-
cise, pacing during the time trial was severely perturbed,
and heart rate, blood pressure and ventilation were
impeded during cycling at 80% of aerobic maximum.
These findings suggest an important role of group III/IV
muscle afferents in the regulation of the cardiorespira-
tory response to rhythmic exercise. In rats, Tsuchimochi
et al. [41] found that stimulation of peripheral μ-opioid
receptors attenuated the exercise pressor reflex and that
this effect could be blocked with naloxone. These find-
ings in humans and animals would suggest that en-
dogenous opioids play a role in the regulation of muscle
afferent traffic, but from our results, it appears that in
healthy, young, physically active subjects doing a 20- to
30-min incremental exercise challenge in normoxia or
severe hypoxia, endogenous opioids are not attenuating
the normal cardiovascular response to exercise through
the stimulation of type III/IV afferent μ-receptors at the
spinal level, leaving the question on their role and sig-
nificance open.
Acute normoxia switch
The limitation of exercise performance in severe hypoxia
is still not well understood [11-13]. Lack of oxygen is
the reason, but it remains unclear what mechanism in
hypoxia leads to an earlier disengagement from an exer-
cise challenge as compared to normoxia. Verges et al.
[13] argue that because biochemical, electromyographic
and mechanical signs of muscle fatigue at exhaustion are
reduced in severe hypoxia compared with normoxia,
muscle metabolic fatigue is not the main factor respon-
sible for impaired whole body exercise performance, as
proposed before [12,15]. Our subjects were able to con-
tinue cycling after reaching their maximum in hypoxia
when switched to normoxia. iEMG, an indicator of loco-
motor muscle drive, increased upon the normoxia
switch, a finding arguing in favour of supraspinal limita-
tion of exercise performance in hypoxia by a rapidly re-
versible withdrawal of motor drive. Amann et al. [42]
found that the degree of hypoxia influences the relative
role of muscle fatigue in the cessation of dynamic exer-
cise with large muscle groups. Those authors proposed a
threshold of SaO2 for a switch from a predominant ef-
fect of peripheral fatigue to a predominant effect of CNS
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ance. They found similar levels of muscle fatigue in task
failure from constant load exercise to exhaustion when
SaO2 averaged 94%, 82% or 76% (FIO2 0.21–0.12), but
not at a SaO2 of 67% (FIO2 0.10). They suggest the dom-
inance of CNS hypoxia over peripheral muscle fatigue in
influencing central motor output below SaO2 levels of
70%–75%. Our results of early exhaustion in hypoxia
with SaO2 below 70% and rapid restoration of exercise
capacity upon the normoxia switch are in accordance
with those contentions.Limits of performance in severe hypoxia
The origins of the signals leading to the cessation of the
central motor drive at exhaustion during heavy large
muscle group exercise in severe hypoxia thus remain un-
clear. Possible candidates controlling the signal to stop
exercise include arterial oxygen (O2) desaturation with
exercise causing marked central nervous system hypoxia,
other factors acting on the respiratory and/or other
higher nervous centres, with or without contribution of
fatigued respiratory muscles, or the effects of pulmonary
hypertension and right ventricular overload [4,12,43,44].
Millet et al. [45] showed in a biceps brachii repeated iso-
metric contraction model that in pronounced hypoxia
(9% O2, SaO2 75%), central drive is diminished inde-
pendently of afferent feedback and peripheral fatigue
and concluded that submaximal performance in severe
hypoxia is related directly to brain oxygenation, results
corroborating those of Goodall et al. [46] who also
showed that peripheral mechanisms of fatigue contribute
relatively more to the reduction in force-generating cap-
acity of the knee extensors following submaximal inter-
mittent isometric contractions in normoxia and mild to
moderate hypoxia, whereas supraspinal fatigue plays a
greater role in more pronounced degrees of hypoxia.Study limitations
Our results pertain to a limited sample size of healthy,
young, trained male subjects and cannot be generalised.
Further limitations to our study design are acknowledged.
Prolonged hypoxia leads to ventilatory acclimatisation
changing ventilation at rest and during exercise. We per-
formed our experiments in acute normobaric hypoxia,
and it is possible that in chronic hypobaric hypoxia, find-
ings would differ. It therefore remains to be described
what the effects of opioids or opioid receptor antagonists
on breathing sensation and exercise performance in con-
ditions of prolonged hypobaric hypoxia would be. Finally,
we used a short incremental exercise protocol to exhaus-
tion. It remains an open question if more prolonged sub-
maximal time trial like exercise would be influenced by
opioid receptor blockade.Conclusions
We compared incremental cycling exercise capacity in
conditions of normoxia and hypoxia after injection of the
opioid antagonist naloxone, in comparison with placebo.
Since naloxone had no effect on the ventilatory response
to exercise nor on the sensation of exertion, neither in
normoxia nor in hypoxia, it follows that endogenous
xopioid receptors do not play a role in the perceived exer-
tion and the regulation of maximal aerobic exercise per-
formance in conditions of severe hypoxia.
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